Skip to main content
. Author manuscript; available in PMC: 2015 Dec 1.
Published in final edited form as: Lancet Oncol. 2014 Nov 12;15(13):1481–1492. doi: 10.1016/S1470-2045(14)70486-3

Figure 1. Summary description of the composition of pooled analytic groups with respect to the individual clinical trials.

Figure 1

(A) The XELOX or FOLFOX versus leucovorin and fluorouracil comparison, (B) the capecitabine with or without oxaliplatin versus leucovorin and fluorouracil with or without oxaliplatin comparison, (C) the XELOX versus capecitabine comparison, and (D) the sensitivity analysis directly comparing XELOX with or without bevacizumab versus FOLFOX with or without bevacizumab.

X-ACT=Xeloda in Adjuvant Colon Cancer Therapy. XELOXA=XELOX in Adjuvant Colon Cancer Treatment. NSABP=National Surgical Adjuvant Breast and Bowel Project. XELOX=capecitabine plus oxaliplatin. mFOLFOX-6=modified FOLFOX-6. FOLFOX=leucovorin and fluorouracil plus oxaliplatin. AVANT=Avastin Adjuvant.